• contact
  • home
  • about
    • our history
    • management
    • board of directors
    • advisors
    • investors & partners
  • approach
  • pipeline
    • CGS-200-5
    • PRL-02
  • news & insights
    • news
    • presentations
    • press releases
    • references (CGS-200-5)
    • references (PRL-02)
  • contact
  • Menu
  • our constellation

    Our current pipeline encompasses brilliant new products that offer promise for highly unmet needs.

our constellation

Our lead product candidate, topical CGS-200-5, is being developed for the management of pain due to osteoarthritis (OA) of the knee.  It has already successfully completed a Phase 2 clinical study for pain due to knee OA and is Phase 3 ready.  PRL-02 utilizes an innovative and patented prodrug of a known active pharmaceutical ingredient (API) and clinical studies will begin in 2Q 2021.

  • CGS-200-5
  • PRL-02
  • home
  • about
  • approach
  • pipeline
  • news & insights
  • contact
© 2020-2021 Propella Therapeutics, Inc. / all rights reserved
  • privacy policy
  • terms of use
  • copyright policy
Scroll to top